Company Overview and News

 
What's in Store for McDermott (MDR) This Earnings Season?

7h zacks
McDermott International, Inc. (MDR - Free Report) is expected to release first-quarter 2018 results before the opening bell on Apr 24. In the preceding three-month period, the company delivered a positive earnings surprise of 233.33% on the back of strong project execution, and increased marine and fabrication activities. Further, the company reported an average positive surprise of 247.07% in the trailing four quarters.
Upvote Downvote

4
MDR / McDermott International, Inc. 8-K (Current Report)

2018-04-18 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
Oil & Gas Stock Roundup: CVX's Gorgon Expansion, MDR & NOV's Operational Updates & More

2018-04-17 zacks
On the news front, U.S. supermajor Chevron Corp. (CVX - Free Report) gave its go-ahead to the $5.1 billion second stage of its massive Gorgon LNG project in Western Australia, while oilfield service providers McDermott International, Inc. (MDR - Free Report) and National Oilwell Varco, Inc. (NOV - Free Report) provided first-quarter operational updates.
Upvote Downvote

1
MDR / McDermott International, Inc. 425 (Prospectus)

2018-04-17 sec.gov
425 Filed by: McDermott International, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934
Upvote Downvote

1
MDR / McDermott International, Inc. 425 (Prospectus)

2018-04-17 sec.gov
425 Filed by: McDermott International, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934
Upvote Downvote

1
MDR / McDermott International, Inc. FILED PURSUANT TO RULE 425 (Prospectus)

2018-04-17 sec.gov
Filed pursuant to Rule 425 Filed by: McDermott International, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934
Upvote Downvote

2
MDR / McDermott International, Inc. FILED PURSUANT TO RULE 425 (Prospectus)

2018-04-17 sec.gov
Filed pursuant to Rule 425 Filed by: McDermott International, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934
Upvote Downvote

 
MDR / McDermott International, Inc. 425 (Prospectus)

2018-04-17 sec.gov
425 Filed by: McDermott International, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934
Upvote Downvote

1
MDR / McDermott International, Inc. 425 (Prospectus)

2018-04-17 sec.gov
425 Filed by: McDermott International, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934
Upvote Downvote

 
BRIEF-Mcdermott International Says ISS Recommends Mcdermott Stockholders Vote "For" Each Of Proposals Relating To Combination With CB&I

2018-04-17 reuters
* MCDERMOTT INTERNATIONAL INC - ISS RECOMMENDS MCDERMOTT STOCKHOLDERS VOTE “FOR” EACH OF PROPOSALS RELATING TO COMBINATION WITH CB&I Source text for Eikon: Further company coverage:
Upvote Downvote

 
Leading Proxy Advisor Firm ISS Recommends McDermott Stockholders Vote “FOR” Each of the Proposals Relating to the Combination with CB&I

2018-04-17 globenewswire
HOUSTON, April 17, 2018 (GLOBE NEWSWIRE) -- McDermott International, Inc. (“McDermott”) (NYSE:MDR) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended that McDermott stockholders vote “FOR” each of the proposals relating to the combination with CB&I (NYSE:CBI).
Upvote Downvote

 
Chicago Bridge & Iron: The Market's Not Making Sense

2018-04-16 seekingalpha
Chicago Bridge & Iron temporarily received investors' favor after management reported positive performance and expectations of a brighter future.
Upvote Downvote

 
[Press] Oil & Gas EPC Market - Analysis of Growth, Trends and Forecasts (2018 - 2023)

2018-04-12 oilvoice
In 2016, the global spending on oil and gas projects was about USD 437 billion, a decrease of nearly 41.7% when compared to that of 2014. Factors, such as a decline in the investments in oil and gas projects and cancellation of projects, worth USD 380 billion since 2014, have resulted in a severe downturn in the global oil & gas EPC market. As a result, it is tough to maintain the profit margins, which has fueled the level of competition between EPC contractors.
Upvote Downvote

2
MDR / McDermott International, Inc. FORM 8-K (Prospectus)

2018-04-12 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
MDR / McDermott International, Inc. FORM 8-K (Prospectus)

2018-04-12 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 580037109